Publications by authors named "Naoko Takasao"
We conducted a randomized phase 3 study to investigate the efficacy and safety of GH treatment in prepubertal Japanese patients with short stature due to deficiency. The patients were randomly allocated to the GH-GH group (n = 10), in which the patients were treated with GH (0.35 mg/kg/wk) subcutaneously once daily for 24 mo, or the no-treatment (NT)-GH group (n = 9), in which the patients were untreated for the first 12 mo and then administered the same dosage of GH for the next 12 mo.
View Article and Find Full Text PDFArticle Synopsis
- Mucopolysaccharidosis type I (MPS I) is a genetic disorder caused by a lack of the enzyme α-L-iduronidase, leading to harmful buildup of glycosaminoglycans that affect multiple organs and the central nervous system.
- Current treatments like enzyme replacement therapy only help with physical symptoms due to the blood-brain barrier preventing enzyme access to the brain, while stem cell transplants are limited by risks of complications.
- A new treatment, lepunafusp alfa (JR-171), combines IDUA with an antibody to enhance enzyme delivery to the brain, showing promising results in a first-in-human study with 18 patients, including successful reduction of harmful substances in both the brain and blood without significant safety concerns
The breakdown of collagenous networks with aging results in hypoactive changes in the skin. Accordingly, reviving stagnant collagen synthesis can help protect dermal homeostasis against aging. We searched for type I collagen biosynthesis-inducing substances in various foods using human dermal fibroblasts and found that cinnamon extract facilitates collagen biosynthesis.
View Article and Find Full Text PDF